Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12499887 | 0.98 | LOXL2 (0.53) | LOXL2DPP4ROCK2MAPTKDM4E | |
| SCHEMBL3653076 | 0.89 | DPP4 (0.51) | LOXL2DPP4ROCK2MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL12499484 | 0.87 | DPP4 (0.50) | LOXL2DPP4ROCK2MAPTKDM4E | |
| SCHEMBL17083284 | 0.87 | LOXL2 (0.54) | LOXL2DPP4ROCK2MAPTKDM4E | |
| SCHEMBL4123831 | 0.86 | DPP4 (0.51) | LOXL2DPP4MAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL17077484 | 0.85 | LOXL2 (0.53) | LOXL2DPP4ROCK2MAPTKDM4E | |
| SCHEMBL27150109 | 0.85 | DPP4 (0.50) | LOXL2DPP4MAPTKDM4EALDH1A1 | |
| SCHEMBL15862210 | 0.84 | LOXL2 (0.59) | LOXL2ROCK2MAPTKDM4EALDH1A1 | |
| SCHEMBL6479787 | 0.84 | ERN1 (0.55) | LOXL2ROCK2CA12CA1CA2 | |
| SCHEMBL9306207 | 0.83 | DPP4 (0.49) | LOXL2DPP4MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921310-B1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA S L (ES) | 2026-01-14 | — | — | EP | disclosed |
| CN-113646299-B | Novel N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE 2) receptor modulators | 梅迪比奥法尔玛公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | MEDIBIOFARMA, S.L. (ES) | 2024-01-16 | — | — | US | disclosed |
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | MEDIBIOFARMA, S.L. (ES) | 2024-01-16 | — | — | US | disclosed |
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | MEDIBIOFARMA, S.L. (ES) | 2024-01-16 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20220117962-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2022-04-21 | — | — | US | disclosed |
| US-20220117962-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2022-04-21 | — | — | US | disclosed |
| EP-3921310-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-12-15 | — | — | EP | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| US-6191171-B1 | ANTAGONISTS, USEFUL IN INHIBITION OR PREVENTION OF CELL ADHESION AND CELL-ADHESION MEDIATED PATHOLOGIES; FOR DRUGS FOR TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| WO-1999026923-A1 | PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117962-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | PTGER2, PTGER4, PTGER1 | LOXL2 477/4885DPP4 2578/4885ROCK2 2073/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | LOXL2 3851/4885DPP4 751/4885ROCK2 2366/4885 |
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | PTGER2, PTGER4, PTGER1 | LOXL2 454/4885DPP4 2494/4885ROCK2 2049/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | LOXL2 433/4885DPP4 2357/4885ROCK2 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.